PDS Biotechnology Corp
For the period ended Jun 30, 2024. Filed Aug 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 13, 2024
PDSB$1.03-4.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
| Three Months Ended June 30, | Six Months Ended June 30, | |||
|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |
| Operating expenses: | ||||
| Research and development expenses | $4,527,698 | $8,004,852 | $11,231,862 | $13,848,538 |
| General and administrative expenses | 4,156,606 | 4,691,321 | 7,550,069 | 8,270,049 |
| Total operating expenses | 8,684,304 | 12,696,173 | 18,781,931 | 22,118,587 |
| Loss from operations | (8,684,304) | (12,696,173) | (18,781,931) | (22,118,587) |
| Interest income (expenses), net | ||||
| Interest income | 675,209 | 750,654 | 1,344,104 | 1,479,995 |
| Interest expense | (1,187,971) | (995,397) | (2,362,716) | (1,962,242) |
| Interest income (expenses), net | (512,762) | (244,743) | (1,018,612) | (482,247) |
| Loss before income taxes | (9,197,066) | (12,940,916) | (19,800,543) | (22,600,834) |
| Benefit for income taxes | 869,169 | 1,406,021 | 869,169 | 1,406,021 |
| Net loss and comprehensive loss | (8,327,897) | (11,534,895) | (18,931,374) | (21,194,813) |
| Per share information: | ||||
| Net loss per share, basic and diluted | $(0.23) | $(0.37) | $(0.53) | $(0.69) |
| Weighted average common shares outstanding, basic, and diluted | 36,693,561 | 30,802,498 | 35,754,715 | 30,616,310 |
Index
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.